AKT1 and breast carcinoma: In breast cancer, increased circCDYL2 stabilizes GRB7, preventing its degradation and boosting its interaction with FAK, which sustains AKT and ERK1/2 pathway activity, leading to trastuzumab resistance.718 Conversely, the reduction of certain circRNAs is likely to cause treatment resistance.